The new paradigm creator for animal‑free, human‑relevant organoid‑chip evaluation

The story of ORGANOPlus
The future of drug development depends on predictive, human-relevant validation.
Preclinical systems still suffer from poor translational predictability and costly late-stage failures.
ORGANOPlus is building a standardized, gut-centered multi-organ validation infrastructure designed to make human biology measurable, reproducible, and scalable.
We are not building better lab models.
WWe are establishing the infrastructure for human-relevant drug development.


MISSON
misson_1.png
Innovative
Preclinical Platform

misson_2.png
Precision-Driven
Drug Validation
misson_3.png
Addressing
High Unmet Needs
Our Journey
2026
Jan
Established OrganoPlus Denmark ApS in Copenhagen

2025
Sep
Signed MOU with Harvard Medical School to co-develop an IBD model with intestinal muscle integration.

Aug
Established Corporate Research Center
CSO invited speaker at EKC 2025 (Vienna, Austria)
CSO invited speaker at China University of Petzroleum (Qingdao)

Jul
Selected as Global Accelerating Company by Suwon City
Entered joint research collaboration with Biospero
Jun
Signed research service agreement with Biospero
Founded ORGANOPlus
Research Institute Location
🇰🇷 Korea Headquarters

ORGANOPlus Co., Ltd.
Suite 85216, 2066 Seobu-ro
Jangan-guSuwon-si
Gyeonggi-do 16419Republic of Korea

🇩🇰 European Subsidiary

ORGANOPlus Denmark ApS
Suite 85216, 2066 Seobu-ro
Lautrupsgade 7
2100 Copenhagen Ø
Denmark